USA flag logo/image

An Official Website of the United States Government

Company Information:

Name: A AND G PHARMACEUTICAL, INC.
Address: A AND G PHARMACEUTICAL, INC.
9130 RED BRANCH RD, STE U
COLUMBIA, MD 21045-
Located in HUBZone: No
Woman-Owned: No
Minority-Owned: No
URL: N/A
Phone: N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $1,110,996.00 7
SBIR Phase II $1,153,871.00 1

Award List:

Development of a novel serum diagnosis for breast cancer

Award Year / Program / Phase: 2004 / SBIR / Phase I
Agency: HHS
Principal Investigator: Ginette Serrero
Award Amount: $99,960.00
Abstract:
DESCRIPTION (provided by applicant): Each year 200,000 women in the US are diagnosed with breast cancer, and 40,000 women will die of the disease. Serum diagnosis for screening breast cancer patients is not yet available. Moreover, there is only limited possibility for monitoring response to… More

Novel Targeted Therapy for Breast Cancer

Award Year / Program / Phase: 2007 / SBIR / Phase I
Agency: HHS
Principal Investigator: Ginette Serrero
Award Amount: $120,600.00
Abstract:
DESCRIPTION (provided by applicant): Breast cancer remains one of the top three cancers to affect and cause mortality in women. Major shortcomings with current treatment are the high level of side effects and insufficient efficacy, particularly for patient s with metastatic disease. Targeted cancer… More

Novel Small Molecule Inhibitor of Rheumatoid Arthritis

Award Year / Program / Phase: 2009 / SBIR / Phase I
Agency: HHS
Principal Investigator: Jun H. Hayashi
Award Amount: $184,029.00
Abstract:
DESCRIPTION (provided by applicant): Lck is a Src family non-receptor tyrosine kinase expressed by T lineage lymphocytes. In T cells, Lck plays an essential role in the generation of antigen-mediated activation signals. Since T cell activation is central to mounting immune response, inhibition of… More

Novel Targeted Therapy for Breast Cancer

Award Year / Program / Phase: 2010 / SBIR / Phase II
Agency: HHS
Principal Investigator: Ginette Serrero
Award Amount: $1,153,871.00
Abstract:
DESCRIPTION (provided by applicant): Breast cancer remains one of the top three cancers to affect and cause mortality in women. Major shortcomings with current treatment are the high level of side effects induced in patients and insufficient efficacy, part icularly for patients with metastatic… More

Serum GP88 biomarker as a surrogate marker for disease progression in breast canc

Award Year / Program / Phase: 2011 / SBIR / Phase I
Agency: HHS
Principal Investigator: Ginette Serrero – 410-884-4100
Award Amount: $113,320.00
Abstract:
DESCRIPTION (provided by applicant): 40,000 women die annually in the US as a result of breast cancer (BC). Although BC can be controlled if detected early, a significant number is not detected until later and these patients are treated using therapies tocontrol both primary tumor and… More

Targeted Therapy for Non Small Cell Lung Carcinoma: In vivo Feasibility Studies

Award Year / Program / Phase: 2012 / SBIR / Phase I
Agency: HHS
Principal Investigator: Ginette Serrero – 410-884-4100
Award Amount: $193,879.00
Abstract:
DESCRIPTION (provided by applicant): Lung Cancer remains the leading cause of cancer and mortality for men and women worldwide. In 2010, there were 222,520 new cases of lung cancer diagnosed in the US, 85% being non small cell lung cancer (NSCLC) and157,300 lung cancer related deaths. Clearly,… More

NOVEL AGENT TO RESTORE SENSITIVITY TO ANTI-ESTROGEN THERAPY

Award Year / Program / Phase: 2012 / SBIR / Phase I
Agency: HHS
Principal Investigator: Ginette P. Serrero – 410-884-4100
Award Amount: $199,380.00
Abstract:
Aromatase Inhibitors (AI) are the preferred hormonal treatment for estrogen receptor positive Breast Cancer (BC) in postmenopausal women and are used to treat approximately 140,000 patients annually in the US. However, ~40% of patients will be, or become resistant to AIs. If sensitivity to AI can be… More

IGF::OT::IGF Title: SMART Fusion: High Affinity Peptide Capture Reagents PoP: 0

Award Year / Program / Phase: 2013 / SBIR / Phase I
Agency: HHS
Principal Investigator: Jun Hayashi – 410-884-4100
Award Amount: $199,828.00
Abstract:
The purpose of this application is to develop realiable, renewable, cost effective, specific, high affinity antipeptide affitnity reagent to be successfully used in mass spec based cancer biomarker detection methods such as SISCAPA, for the analysis of patient plasma. Early detection of cancer is a… More